Regulatory Update

Weekly Regulatory News

Starting August 2024, the Agency will process requests via RIMS, expand consultations for China's med device industry, and launch an NPRA pilot project.

Published on:
August 13, 2024

SERBIA

Notice to Users of Serbia's Medicines and Medical Devices Agency August 2, 2024

Starting August 2024, the Agency for Medicines and Medical Devices will begin processing certain requests through the RIMS system. From August 5, this includes documentary quality control requests for drugs, and from August 12, it will expand to include various clinical trial-related requests, such as importing drugs for trials and reporting on clinical trials.

Three Important Points:

  1. Implementation Date: Requests will begin transitioning to the RIMS system on August 5 and August 12, 2024.
  2. Types of Requests: Initial requests include documentary quality control for drugs, followed by requests related to clinical trials, including imports, changes, and reporting.
  3. RIMS System Use: The shift to the RIMS system aims to streamline and centralize the submission and processing of these requests.

CHINA

Supplementary Notice: Adjustment of Pre-Acceptance Consultation for Medical Devices

To further support the development of China's medical device industry, Hebei, Shandong, and Hubei Medical Device Innovation Service Stations have been added as participating units for pre-registration technical consultations. These consultations will begin on August 12, 2024, offering high-quality guidance to local medical device manufacturers. Consultations will be held every Thursday, with specific times and locations provided by each service station.

Three Important Points:

  1. New Service Stations Added: Hebei, Shandong, and Hubei Medical Device Innovation Service Stations are now included in the pre-registration technical consultation process starting August 12, 2024.
  2. Consultation Availability: Consultations will be available all day every Thursday, with specific times and schedules provided by each service station.
  3. Target Audience: The consultations are aimed at domestic Class III medical device developers and manufacturers, as well as companies registered in China for imported medical devices.

Learn more about China Medical Device Registration & Approval.

MALAYSIA

Notice to PRHs: Revised Categories & Criteria for New/Additional Indication Applications – Pilot Study

The NPRA is expanding its reliance approach to include new/additional indication applications through a 12-month pilot project starting on August 1, 2024. The project involves revised categories and criteria, as detailed in Appendix I. While NPRA aims to test new processes, they are also managing a high volume of variation applications with the same resources, making applicant cooperation crucial.

Three Important Points:

  1. The pilot project will test new categories and criteria for new/additional indication applications over 12 months, starting August 1, 2024.
  2. The NPRA is handling both the pilot study and a high volume of variation applications, so applicant cooperation in planning and scheduling is essential.
  3. Applicants should consult the respective head of sections for any queries related to the pilot project.

Learn more about MDA Malaysia Medical Device Registration.

Subscribe to newsletter
Subscribe to receive the latest blog posts to your inbox every week.
By subscribing, you agree to our Terms and Conditions.
Thank you for subscribing!
Oops! Something went wrong while submitting the form.
Read more

Latest News

Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.

Regulatory Update
January 29, 2025

Wrapping up January 2025, medical device regulatory developments include new forms for NBs in Europe, new PMS guidance in the UK, an expedited approval partnership between China and Malaysia, and warnings of supply chain disruptions for pediatric patients in the US.

Regulatory Update
January 23, 2025

Medical device regulatory developments from the US and Thailand include: final FDA guidance on modular review for premarket approval applications and humanitarian device exemptions, and new expedited regulatory routes for low-risk devices and chronic disease prevention devices in Thailand.

Regulatory Update
January 16, 2025

This week, we are reporting on medical device regulatory updates from Canada, Europe, Brazil, and China. China's NMPA released registration review timelines, clarification on MDR and IVDR vigilance terms is now available, and Health Canada updated validation rules for non-eCTD transactions.

To kick off 2025, we bring you a round up of medical device regulatory updates from across Europe and the US, including a new position paper from TEAM-NB on MDR certification processes and numerous guidance updates from the US FDA.

Contact us
Request information

Let's Talk,
Anywhere You Are.

Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.

Our closest representative will get back to you within 24 hours.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Latest Blog Content

Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.

Blog Article

The official IVDR transition period is here. IVDR expert Dr. Oliver Eikenberg discusses how IVD manufacturers should take action, starting with how to implement IVDR QMS requirements for the May 2025 deadline.

Kuala Lumpur Malaysia Skyline
Blog Article
Pure Global Team attends IMDEC 2024 in Malaysia

Pure Global participated in IMDEC 2024 in Kuala Lumpur to discuss the latest advancements in medical technology, regulatory efficiency, and the role of AI in transforming the industry. Highlights included updates from the Malaysian Medical Device Authority (MDA) that showcased their commitment to driving regional leadership in medical device regulation and innovation.

Pure Global 2024 Year in Review
Blog Article
Pure Global 2024 Year in Review

As 2024 comes to a close, Pure Global proudly reflects on a transformative year marked by substantial growth, cutting-edge innovation, and impactful collaborations.

Risk increases compliance chalenges under IVDR
Blog Article
What are the challenges under IVDR?

IVD manufacturers cite the new classification system, detailed definitions for intended purposes, and the need for verification of clinical evidence as key challenges under the IVDR.